Seres Therapeutics Yönetim

Yönetim kriter kontrolleri 3/4

Seres Therapeutics CEO'su Eric Shaff, Jan2019 tarihinde atandı, in görev süresi 5.83 yıldır. in toplam yıllık tazminatı $ 3.16M olup, şirket hissesi ve opsiyonları dahil olmak üzere 21.7% maaş ve 78.3% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.097% ine doğrudan sahiptir ve bu hisseler € 90.19K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.2 yıl ve 8.2 yıldır.

Anahtar bilgiler

Eric Shaff

İcra Kurulu Başkanı

US$3.2m

Toplam tazminat

CEO maaş yüzdesi	21.7%
CEO görev süresi	5.8yrs
CEO sahipliği	0.1%
Yönetim ortalama görev süresi	5.2yrs
Yönetim Kurulu ortalama görev süresi	8.2yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Eric Shaff'un ücretlendirmesi Seres Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$68m
Jun 30 2024	n/a	n/a	-US$162m
Mar 31 2024	n/a	n/a	-US$83m
Dec 31 2023	US$3m	US$685k	-US$114m
Sep 30 2023	n/a	n/a	-US$141m
Jun 30 2023	n/a	n/a	-US$153m
Mar 31 2023	n/a	n/a	-US$265m
Dec 31 2022	US$4m	US$662k	-US$250m
Sep 30 2022	n/a	n/a	-US$231m
Jun 30 2022	n/a	n/a	-US$103m
Mar 31 2022	n/a	n/a	-US$87m
Dec 31 2021	US$10m	US$625k	-US$66m
Sep 30 2021	n/a	n/a	-US$34m
Jun 30 2021	n/a	n/a	-US$132m
Mar 31 2021	n/a	n/a	-US$105m
Dec 31 2020	US$3m	US$590k	-US$89m
Sep 30 2020	n/a	n/a	-US$90m
Jun 30 2020	n/a	n/a	-US$76m
Mar 31 2020	n/a	n/a	-US$66m
Dec 31 2019	US$2m	US$540k	-US$70m
Sep 30 2019	n/a	n/a	-US$73m
Jun 30 2019	n/a	n/a	-US$78m
Mar 31 2019	n/a	n/a	-US$95m
Dec 31 2018	US$1m	US$435k	-US$99m
Sep 30 2018	n/a	n/a	-US$107m
Jun 30 2018	n/a	n/a	-US$92m
Mar 31 2018	n/a	n/a	-US$92m
Dec 31 2017	US$2m	US$377k	-US$89m

Tazminat ve Piyasa: Eric 'nin toplam tazminatı ($USD 3.16M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 479.80K ).

Tazminat ve Kazançlar: Eric 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Eric Shaff (48 yo)

5.8yrs

Görev süresi

US$3,158,336

Tazminat

Mr. Eric D. Shaff, M.B.A., serves as President and Chief Executive Officer at Seres Therapeutics, Inc. since January 15, 2019 and serves as its Director since January 2019. He served as Chief Operating Off...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Eric Shaff	President	5.8yrs	US$3.16m	0.097% € 90.2k
Lisa von Moltke	Executive VP & Chief Medical Officer	4.7yrs	US$1.57m	0.018% € 16.6k
Teresa Young	Executive VP and Chief Commercial & Strategy Officer	4.4yrs	US$1.82m	0.052% € 48.3k
Marella Thorell	Executive VP & CFO	less than a year	Veri yok	Veri yok
David Ege	Executive VP & Chief Technology Officer	4.1yrs	US$5.32m	0.046% € 42.4k
Matthew Henn	Executive VP & Chief Scientific Officer	5.8yrs	US$1.67m	0.045% € 41.5k
Carlo Tanzi	Investor Relations Officer	9yrs	Veri yok	Veri yok
Thomas DesRosier	Chief Legal Officer	8.5yrs	US$1.44m	0.078% € 72.9k
Caroline Holda	Assistant General Counsel	no data	Veri yok	Veri yok

5.2yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim: 1S9 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Eric Shaff	President	5.8yrs	US$3.16m	0.097% € 90.2k
Willard Dere	Independent Director	7.3yrs	US$225.23k	0.019% € 17.3k
Dennis Ausiello	Independent Director	9.6yrs	US$222.27k	0% € 0
Kurt Graves	Independent Director	9yrs	US$219.23k	0% € 0
Richard Kender	Independent Director	10.1yrs	US$232.69k	0.037% € 34.7k
Mark Wilcox	Member of Scientific Advisory Board	9.8yrs	Veri yok	Veri yok
Andrew Goodman	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Curtis Huttenhower	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Paul Biondi	Independent Director	4.7yrs	US$211.73k	0.028% € 26.0k
Stephen Berenson	Independent Chairman	5.3yrs	US$249.23k	0.0021% € 2.0k
Robert Jenq	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Elhanan Borenstein	Member of Scientific Advisory Board	no data	Veri yok	Veri yok

8.2yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 1S9 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.2 yıldır).

Seres Therapeutics Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Seres Therapeutics Appoints Marella Thorell as Executive Vice President

Insufficient new directors

Seres Therapeutics, Inc. Announces the Appointment of Claire M. Fraser, Ph.D., to Its Board of Directors

Seres Therapeutics, Inc., Annual General Meeting, Jun 22, 2022

Seres Therapeutics Appoints Paula Cloghessy as Executive Vice President, Chief People Officer

Recent updates

New minor risk - Market cap size

Third quarter 2024 earnings released: US$0.33 loss per share (vs US$0.37 loss in 3Q 2023)

New major risk - Financial position

Seres Therapeutics, Inc. to Report Q3, 2024 Results on Nov 13, 2024

Lucien Selce and MKT Capital Issue Open Letter to Board of Seres Therapeutics Regarding Reported Engagement with Nestlé

Seres Therapeutics, Inc. Announces Topline Clinical Data from Cohort 2 of its SER-155 Phase 1b Placebo-Controlled Study in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

First half 2024 earnings released: US$0.49 loss per share (vs US$0.20 loss in 1H 2023)

Seres Therapeutics, Inc. announced that it expects to receive $15.000001 million in funding from Société des Produits Nestlé S.A.

Seres Therapeutics, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Nestle's Health Unit to Take Full Control of Microbiota-Based Therapeutic

New minor risk - Market cap size

First quarter 2024 earnings released: US$0.28 loss per share (vs US$0.56 loss in 1Q 2023)

Seres Therapeutics, Inc. to Report Q1, 2024 Results on May 08, 2024

Seres Therapeutics Receives Non-Compliance Letter from The Nasdaq Stock Market LLC Related to Nasdaq Listing Rule 5450(a)(1)

Seres Therapeutics Receives Non-Compliance Letter from The Nasdaq Stock Market LLC Related to Nasdaq Listing Rule 5450(a)(1)

New minor risk - Market cap size

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

New minor risk - Financial position

Full year 2023 earnings released: US$0.89 loss per share (vs US$2.32 loss in FY 2022)

No longer forecast to breakeven

Seres Therapeutics Appoints Marella Thorell as Executive Vice President

Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155

Forecast to breakeven in 2026

New major risk - Negative shareholders equity

Seres Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Second quarter 2023 earnings released: EPS: US$0.36 (vs US$0.70 loss in 2Q 2022)

Seres Therapeutics, Inc. and Nestle Health Science Present Late-Breaking Data on VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection in Adults, at ASM Microbe 2023

Seres Therapeutics, Inc. and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™

Seres Therapeutics Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination in the Gastrointestinal Microbiome

First quarter 2023 earnings released: US$0.56 loss per share (vs US$0.61 loss in 1Q 2022)

Full year 2022 earnings released: US$2.32 loss per share (vs US$0.71 loss in FY 2021)

Seres Therapeutics' Investigational Ser-109 Ecospor Iv Study Data Publishes in Jama Network Open

Seres Therapeutics, Inc. Announces Initiation of Enrollment in SER-155 Phase 1B Study Cohort 2 in Individuals Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Insufficient new directors

Seres Therapeutics, Inc. Announces the Appointment of Claire M. Fraser, Ph.D., to Its Board of Directors

Third quarter 2022 earnings released: US$0.49 loss per share (vs US$0.74 profit in 3Q 2021)

Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection for Priority Review

Seres Therapeutics, Inc. Announces the Publication of Phase 3 Clinical Data in the Journal of the American Medical Association

Seres Therapeutics Announces Completion of Rolling BLA Submission to FDA for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection

Second quarter 2022 earnings released: US$0.70 loss per share (vs US$0.53 loss in 2Q 2021)

Seres Therapeutics, Inc. Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection

Seres Therapeutics Presents Phase III Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting

Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic Ser-109 for Recurrent C. Difficile Infection At the Digestive Disease Week (Ddw) Annual Meeting

First quarter 2022 earnings released: US$0.61 loss per share (vs US$0.39 loss in 1Q 2021)

Seres Therapeutics, Inc., Annual General Meeting, Jun 22, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Seres Therapeutics Appoints Paula Cloghessy as Executive Vice President, Chief People Officer

Seres Therapeutics, Inc. Announces the Publication in the New England Journal of Medicine of Data from Its Phase 3 ECOSPOR III study evaluating SER-109

Seres Therapeutics, Inc. Announces Preliminary SER-287 Phase 2b ECO-RESET Study Microbiome Data Analysis

Seres Therapeutics Announces First Patient Enrolled in Phase 1B Study of SER-155

Third quarter 2021 earnings released: EPS US$0.74 (vs US$0.36 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.53 loss per share (vs US$0.28 loss in 2Q 2020)

Seres Therapeutics, Inc. Announces Topline Results from the Phase 2B ECO-RESET Study Evaluating SER-287 in Patients with Mild-To-Moderate Ulcerative Colitis

Seres Therapeutics, Inc.(NasdaqGS:MCRB) dropped from Russell 3000E Index

Seres Therapeutics Presents Research from Its Early-Stage Microbiome Therapeutic Oncology Programs At the 2021 American Society of Clinical Oncology (Asco) Annual Meeting

Seres Therapeutics Announces U.S. Food and Drug Administration Clearance of Investigational New Drug for SER-155

Seres Therapeutics, Inc. Presents Data Across Its Broad Microbiome Pipeline Including New 24-Week Data from Ser-109 Phase 3 Ecospor III Study in Recurrent C. Difficile Infection At Digestive Disease Week 2021

First quarter 2021 earnings released: US$0.39 loss per share (vs US$0.28 loss in 1Q 2020)

Seres Therapeutics, Inc. Announces Discontinuation of Enrollment in SER-401 Study in Metastatic Melanoma

Full year 2020 earnings released: US$1.12 loss per share (vs US$1.24 loss in FY 2019)

Revenue beats expectations

Seres Therapeutics Announces Achievement of Target Enrollment in SER-287 Phase 2b ECO-RESET Study for Ulcerative Colitis

New 90-day low: €17.40

New 90-day low: €18.80

Seres Therapeutics, Inc. Therapeutics to Present SER-109 Phase 3 Mechanistic Data At Keystone Symposium

Seres Therapeutics, Inc. Publishes Positive SER-287 Phase 1b Ulcerative Colitis Study Results in Journal Gastroenterology

New 90-day low: €19.00

New 90-day low: €19.40

Revenue misses expectations

Third quarter 2020 earnings released: US$0.36 loss per share